Different hCG assays to measure ectopic hCG secretion in bladder carcinoma patients

Móra, Josefina; Gascón, N.; Tabernero, J.; Rodrı́guez-Espinosa, José; González‐Sastre, Francesc

doi:10.1038/bjc.1996.493

Cited by 14 publications

(6 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was an additional non-pregnant patient with elevated intact hCG possibly attributable to pituitary hCG or from the patient’s urothelial carcinoma which has been shown to produce intact hCG on rare occasion. 5–8 Intact hCG, total beta-hCG, and FSH on this sample were 235, 283, and 165 mIU/mL, respectively. Normally, FSH is ≤ 32 in premenopausal patients.…”

Section: Resultsmentioning

confidence: 78%

Reducing False-Positive Pregnancy Test Results in Patients With Cancer

McCash

Goldfrank

Pessin

et al. 2017

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

OBJECTIVE To assess whether the use of a lab test specific for intact human chorionic gonadotropin (hCG) would reduce the number of false-positive pregnancy cases. METHODS From 10/21/14 – 01/20/15 and 04/01/15 – 06/02/15, all serum samples sent for pregnancy screening at a large cancer center with a value of ≥5 mIU/mL total β-hCG were frozen and stored, then re-tested using intact hCG reagent. We compared the accuracy of total β-hCG and intact hCG results for the diagnosis of clinically confirmed pregnancy. A negative test was defined as ≤14 mIU/mL, our current institutional cutoff. We also assessed a cutoff of <5 mIU/mL, a historical cutoff to rule out pregnancy. RESULTS We performed intact hCG testing on 64 patient samples, of which 34 had originally resulted positive when tested for total β-hCG. These included 21 cases of clinically confirmed pregnancy, and 13 false positive cases. No women were pregnant when their intact hCG concentration was ≤14 mIU/mL, and all pregnancies were detected at and above this concentration. Intact hCG reduced the number of false positive pregnancy tests from 13 to 1, a 92% reduction [95% Confidence Interval (CI) 64–99%], corresponding to a reduction in the false-positive rate from 38% [95% CI 22–56%] to 3% [95% CI 1–15%]. CONCLUSION The use of intact hCG reagent in cancer patients reduces the rate of false positive pregnancy tests without increasing the rate of false negative tests.

show abstract

Section: Resultsmentioning

confidence: 78%

Reducing False-Positive Pregnancy Test Results in Patients With Cancer

McCash

Goldfrank

Pessin

et al. 2017

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

“…Mora and associates [ 25 ] evaluated the clinical performance of assays measuring intact human chorionic gonadotropin alone (i-hCG), intact and nicked human chorionic gonadotropin (i-hCG and hCGn), free beta-subunit (free beta-hCG) and total beta-human chorionic gonadotropin (t-hCG) using different commercial kits, in a group of bladder carcinoma patients with ectopic human chorionic gonadotropin (hCG) secretion, at diagnosis and during treatment. The diagnostic sensitivity obtained ranged between 63.6% and 75.7% (t-hCG assays), 72.7% (free beta-hCG assay), 18.2% (i-hCG and hCGn) and 6% (i-hCG assay).…”

Section: Discussionmentioning

confidence: 99%

The expression of Beta Human Chorionic Gonadotrophin (beta-HCG) in human urothelial carcinoma)

Venyo¹,

Herring²,

Greenwood³

et al. 2011

Pan Afr Med Jrnl

View full text Add to dashboard Cite

Introduction Studies regarding the immuno-histological expression and relevance of Beta-Human Chorionic Gonadotrophin (=-HCG) in urothelial carcinoma are few. There is also no clear cut way of predicting exactly which superficial urothelial carcinomas would subsequently recur or progress and which muscle-invasive urothelial tumours would progress. The objective of the study was to study the immunohistological expression of =-HCG in urothelial carcinoma with regards to grade, category and outcome following treatment Methods The expression of =-HCG in urothelial carcinomas of 86 patients was studied with regards to grade, stage and outcome using an immunohistological (ABC) method and formalin fixed/paraffin embedded tumours. Results Of the 86 tumours (55 superficial and 31 muscle-invasive) studied 45, 16 and 26 were graded as G1, G2, and G3 respectively. Thirteen of the 55 superficial tumours were positively stained for β=-HCG and 42 negatively stained. Twenty of the 31 muscle-invasive tumours studied were positively stained for β=-HCG and 11 were negative. Of the 13 β=-HCG positive superficial tumours only one did not recur at follow up and 12 subsequently recurred, of the 42 β=-HCG negative superficial tumours 19 did not recur and 23 recurred. Only one of twenty patients with β=-HCG positive muscle-invasive tumours survived; 6 of 11 patients with β=-HCG negative muscle-invasive tumours survived. The results indicate that positive staining of the tumours was more commonly associated with tumours of higher grade, higher stage and inferior outcome. Conclusion The Immunohistological expression of β=-HCG would likely predict superficial tumours that would recur and muscle-invasive tumours with inferior outcome.

show abstract

“…AFP assay uses beads coated with monoclonal murine anti-AFP and alkaline phosphatase conjugated to polyclonal rabbit anti-AFP (23). βHCG assay uses beads coated with monoclonal murine anti-βHCG and alkaline phosphatase conjugated to polyclonal ovine anti-βHCG (24). Reactions were linear up to 300 KU/L for AFP and up to 5,000 units/L for βHCG.…”

Section: Translational Relevancementioning

confidence: 99%

Sunitinib Inhibits Tumor Growth and Synergizes with Cisplatin in Orthotopic Models of Cisplatin-Sensitive and Cisplatin-Resistant Human Testicular Germ Cell Tumors

Castillo

Piulats²,

Muro³

et al. 2009

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Germ cell tumors (GCT) of the testis are highly curable, but those patients who are refractory to cisplatin (CDDP)-based combination chemotherapy have a poor prognosis. Therefore, identifying new alternatives for treatment remains a priority. Several studies support an important role for angiogenesis in GCTs, suggesting that antiangiogenic treatment might be a good alternative. Sunitinib is an oral multitarget tyrosine kinase receptor inhibitor with antiangiogenic and antitumor activities. In the present study, we evaluated the effect of sunitinib, CDDP, or the combination of both drugs using an orthotopic model of human testicular GCT. Experimental Design: Mice were implanted with four different testicular tumors: a yolk sac, two choriocarcinomas, and a CDDP-resistant choriocarcinoma variant induced in mice by continuous exposure to CDDP. Mice were treated with vehicle, CDDP, sunitinib, or the combination of both drugs and their effects on tumors were analyzed. Results: We observed a significant inhibition in tumor growth accompanied by longer survival after sunitinib treatment. Combination therapy with CDDP significantly enhanced these effects. Sunitinib induced apoptosis, reduced tumor cell proliferation and tumor vasculature, and inhibited vascular endothelial growth factor receptor 1, 2, and 3 and platelet-derived growth factor receptor α phosphorylation without affecting phosphorylation of other tyrosine kinase receptors. More importantly, tumor growth inhibition induced by sunitinib was also observed in the induced CDDP-resistant choriocarcinoma model. Conclusions: Taken together, these results suggest that sunitinib might be a new alternative for treatment of CDDP-refractory patients.

show abstract

Different hCG assays to measure ectopic hCG secretion in bladder carcinoma patients

Cited by 14 publications

References 14 publications

Reducing False-Positive Pregnancy Test Results in Patients With Cancer

Reducing False-Positive Pregnancy Test Results in Patients With Cancer

The expression of Beta Human Chorionic Gonadotrophin (beta-HCG) in human urothelial carcinoma)

Sunitinib Inhibits Tumor Growth and Synergizes with Cisplatin in Orthotopic Models of Cisplatin-Sensitive and Cisplatin-Resistant Human Testicular Germ Cell Tumors

Contact Info

Product

Resources

About